-
1.发明公开PROCESS FOR THE PREPARING ZIPRASIDONE MONOHYDROCHLORIDE HYDRATE 审中-公开用于生产ZIPRASIDONMONOHYDROCHLORID水合物
公开(公告)号：EP1687300A4
公开(公告)日：2007-08-01
申请号：EP03778599
申请日：2003-11-28
申请人： WOCKHARDT LTD , JAWEED MUKARRAM SIDDIQUI MOHAM , MERWADE ARAVIND YEKANATHSA , SINGH KUMAR KAMLESH LAXMI , SOLANKI PAWAN VRAJLAL
发明人： JAWEED MUKARRAM SIDDIQUI MOHAM , MERWADE ARAVIND YEKANATHSA , SINGH KUMAR KAMLESH LAXMI , SOLANKI PAWAN VRAJLAL
IPC分类号： C07D417/04 , C07D417/12
CPC分类号： C07D417/12
摘要： The present invention describes a process for preparing 5-(2-(4-1,2-benzisothiazol-3-yl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one (Ziprasidone) monohydrochloride hydrate or a pharmaceutically acceptable acid addition salt thereof, which is well known agent for treating various disorders including schizophrenia, migraine pain and anxiety. The manufacturing process of Ziprasidone comprises the reaction of hydrochloride salt of 1,2-benzisothiazole-3-piprazinyl with 2-Chloroethyl-6-chlorooxindole in aqueous sodium carbonate solution. Its hydrochloride salt is prepared in aqueous methanol using hydrogen chloride.
-
2.发明公开A NOVEL PROCESS FOR THE MANUFACTURE OF (+)-(S)-CLOPIDOGREL BISULFATE FORM-I 有权制造（+） - （S） - 氯吡格雷二硫化物FORM-I的新方法
公开(公告)号：EP1651646A1
公开(公告)日：2006-05-03
申请号：EP03817742.4
申请日：2003-08-04
申请人： Wockhardt Limited , Jaweed Mukarram, Siddiqui Mohammed , Merwade, Aravind Yekanathsa , Khan, Anjum Reyaz
发明人： JAWEED MUKARRAM, Siddiqui Mohammed, Wockhardt Ltd. , MERWADE, Aravind Yekanathsa, Wockhardt Ltd. , KHAN, Anjum Reyaz, Wockhardt Ltd.
IPC分类号： C07D471/04
CPC分类号： C07D495/04
摘要： The present invention relates to a novel process for the manufacture of blood-platelet aggregation inhibiting agent. In particular, the present invention is directed to a process for the manufacture of Methyl-(+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-S-(4H)acetate bisulfate Form-I.
摘要翻译： 本发明涉及一种制备血小板聚集抑制剂的新方法。 具体地说，本发明涉及制备（+） - （S）-α-（2-氯苯基）-6,7-二氢噻吩并[3,2-c]吡啶-5-（ 4H）乙酸盐硫酸氢盐形式-I。
-
3.发明授权A NOVEL PROCESS FOR THE MANUFACTURE OF (+)-(S)-CLOPIDOGREL BISULFATE FORM-I 有权新方法的（+）的制备 - （S）-CLOPIDOGRELBISULFAT FORM我
公开(公告)号：EP1651646B1
公开(公告)日：2012-05-09
申请号：EP03817742.4
申请日：2003-08-04
申请人： Wockhardt Limited , Jaweed Mukarram, Siddiqui Mohammed , Merwade, Aravind Yekanathsa , Khan, Anjum Reyaz
发明人： JAWEED MUKARRAM, Siddiqui Mohammed, Wockhardt Ltd. , MERWADE, Aravind Yekanathsa, Wockhardt Ltd. , KHAN, Anjum Reyaz, Wockhardt Ltd.
IPC分类号： C07D495/04 , A61K31/4738 , A61P9/00
CPC分类号： C07D495/04
摘要： The present invention relates to a novel process for the manufacture of blood-platelet aggregation inhibiting agent. In particular, the present invention is directed to a process for the manufacture of Methyl-(+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-S-(4H)acetate bisulfate Form-I.
-
4.发明公开A NOVEL PROCESS FOR THE MANUFACTURE OF (+)-(S)-CLOPIDOGREL BISULFATE FORM-I 有权NEUES VERFAHREN ZUR HERSTELLUNG VON（+） - （S）-CLOPIDOGRELBISULFAT FORM-I
公开(公告)号：EP1651646A4
公开(公告)日：2007-03-21
申请号：EP03817742
申请日：2003-08-04
IPC分类号： C07D495/04 , A61K31/4738 , A61P9/00
CPC分类号： C07D495/04
摘要： The present invention relates to a novel process for the manufacture of blood-platelet aggregation inhibiting agent. In particular, the present invention is directed to a process for the manufacture of Methyl-(+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-S-(4H)acetate bisulfate Form-I.
摘要翻译： 本发明涉及一种制备血小板聚集抑制剂的新方法。 具体地说，本发明涉及制备（+） - （S）-α-（2-氯苯基）-6,7-二氢噻吩并[3,2-c]吡啶-5-（ 4H）乙酸盐硫酸氢盐形式-I。
-
5.发明公开PROCESS FOR THE PREPARING ZIPRASIDONE MONOHYDROCHLORIDE HYDRATE 审中-公开用于生产ZIPRASIDONMONOHYDROCHLORID水合物
公开(公告)号：EP1687300A1
公开(公告)日：2006-08-09
申请号：EP03778599.5
申请日：2003-11-28
申请人： Wockhardt Limited , Jaweed Mukarram, Siddiqui Mohammed , Merwade, Aravind Yekanathsa , Singh, Kumar Kamlesh Laxmi , Solanki, Pawan Vrajlal
发明人： JAWEED MUKARRAM, Siddiqui Mohammed Wockhardt Ltd. , MERWADE, Aravind Yekanathsa Wockhardt Limited , SINGH, Kumar Kamlesh Laxmi Wockhardt Limited , SOLANKI, Pawan Vrajlal Wockhardt Limited
IPC分类号： C07D417/04
CPC分类号： C07D417/12
摘要： The present invention describes a process for preparing 5-(2-(4-1,2-benzisothiazol-3-yl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one (Ziprasidone) monohydrochloride hydrate or a pharmaceutically acceptable acid addition salt thereof, which is well known agent for treating various disorders including schizophrenia, migraine pain and anxiety. The manufacturing process of Ziprasidone comprises the reaction of hydrochloride salt of 1,2-benzisothiazole-3-piprazinyl with 2-Chloroethyl-6-chlorooxindole in aqueous sodium carbonate solution. Its hydrochloride salt is prepared in aqueous methanol using hydrogen chloride.
-
-
-
-
搜索结果
5 条记录 (耗时 0.007 秒)
